Same sparkle, different story: how lab-grown diamonds are transforming the market 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
NEW YORK, May 04, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Utah on behalf of investors who purchased Myriad Genetics, Inc. ("Myriad") (NASDAQ:MYGN) securities between August 13, 2014 and March 12, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-c/myriad-genetics-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for the Company’s hereditary cancer testing; (ii) the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action; (iii) Myriad’s revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable; and (iv) as a result, Myriad’s public statements were materially false and misleading at all relevant times. On March 12, 2018, Myriad Genetics filed an 8-K with the United States Securities and Exchange Commission disclosing the receipt of a subpoena from the Department of Health and Human Services concerning “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid.”
If you suffered a loss in Myriad you have until June 19, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/myriad-genetics-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
